PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Idhifa Prior Authorization Policy
- Idhifa® (enasidenib tablets – Celgene/Servier/Bristol-Myers Squibb)

REVIEW DATE: 03/08/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW
Idhifa, an isocitrate dehydrogenase-2 *(IDH2*) inhibitor, is indicated for the treatment of relapsed or refractory **acute myeloid leukemia** in adults with an *IDH2* mutation as detected by an FDA-approved test.[1]

Guidelines
The National Comprehensive Cancer Network (NCCN) guidelines on acute myeloid leukemia (version 1.2023 – March 3, 2023) note Idhifa as an alternative for *IDH2* mutated AML in a variety of clinical scenarios, such as treatment induction, follow-up after induction therapy, consolidation therapy, or relapsed or refractory disease (category 2A).

POLICY STATEMENT
Prior Authorization is recommended for prescription benefit coverage of Idhifa. All approvals are provided for the duration noted below.

- **Idhifa® (enasidenib tablets (Celgene/Servier/Bristol-Myers Squibb) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

FDA-Approved Indication

1. **Acute Myeloid Leukemia.** Approve for 1 year if the patient meets the following criteria (A and B):
   A) Patient is ≥ 18 years of age; AND
   B) Patient has isocitrate dehydrogenase-2 (*IDH2*) mutation-positive disease as detected by an approved test.

CONDITIONS NOT COVERED

- **Idhifa® (enasidenib tablets (Celgene/Servier/Bristol-Myers Squibb) is(are) considered experimental, investigational or unproven for ANY other use(s).**

REFERENCES

1. Idhifa® tablets [prescribing information]. Summit, NJ: Celgene; November 2020.
2. The NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 1.2023 – March 3, 2023). © 2023 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on March 6, 2023.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	**Acute Myeloid Leukemia:** A requirement was added that the patient is ≥ 18 years of age.	02/23/2022
Selected Revision	**Acute Myeloid Leukemia:** The duration of approval was changed from 3 years to 1 year.	06/22/2022
Annual Revision	No criteria changes.	03/08/2023